Daffodil International University
Faculties and Departments => Faculty Sections => Faculty Forum => Topic started by: SSH Shamma on December 25, 2017, 11:41:25 PM
-
Kymriah is a newly FDA-approved cancer gene therapy treatment from the drug company Novartis. It's part of a new class of therapy called CAR-T, which is made by "harvesting a patient's own disease-fighting T-cells, genetically engineering them to target specific proteins on cancer cells, and replacing them to circulate possibly for years, seeking out and attacking cancer," according to Reuters.
It's not cheap — it costs $475,000 per patient — but the results in patients with aggressive blood cancer are unprecedented. In fact, 83 percent of patients were cancer-free after three months with one dose (they continued to respond after six months, according to new reports).
-
Thanks for sharing.